Phipps covers the Healthcare sector, focusing on stocks such as Amgen, Agenus, and Bristol Myers. According to TipRanks, Phipps has an average return of -6.2% and a 41.33% success rate on recommended stocks.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Bristol Myers with a $79.18 average price target, which is a 4.78% upside from current levels. In a report released on July 28, Atlantic Equities also maintained a Buy rating on the stock with a $83.00 price target.
BMY market cap is currently $161.4B and has a P/E ratio of 25.11.
Based on the recent corporate insider activity of 33 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of BMY in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Founded in 1933, New York-based Bristol-Myers Squibb Co. is a global pharmaceutical company, which engages in the development, licensing, manufacturing, distribution, and sale of biopharmaceutical products in several therapeutic areas. These include cancer, HIV/AIDS, cardiovascular disease, diabetes, hepatitis, rheumatoid arthritis and psychiatric disorders.
Read More on BMY:
- Data Storage (DTST) Gets a Buy from Maxim Group
- Boxlight (BOXL) Receives a Buy from Maxim Group
- Maxim Group Remains a Buy on Biolase (BIOL)
- Sientra (SIEN) Receives a Buy from Maxim Group
- Analysts Offer Insights on Healthcare Companies: SELLAS Life Sciences Group (SLS) and Processa Pharmaceuticals (PCSA)